Dopamine Dysregulation Syndrome in Parkinson Disease and Remission After Treatment With Aripiprazole.

Szczegóły

Tytuł:: Dopamine Dysregulation Syndrome in Parkinson Disease and Remission After Treatment With Aripiprazole.
Autorzy:: Al-Qassabi A
Al Sinani A
Źródło:: Journal of clinical psychopharmacology [J Clin Psychopharmacol] 2022 Mar-Apr 01; Vol. 42 (2), pp. 209-210.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Publication: Baltimore Md : Williams And Wilkins
Original Publication: Baltimore, Md. : Williams & Wilkins, [c1981-
MeSH Terms:: Antipsychotic Agents*/adverse effects
Parkinson Disease*/drug therapy
Quinolones*
Aripiprazole/pharmacology ; Dopamine ; Dopamine Agonists ; Humans
References:: Giovannoni G, O'Sullivan JD, Turner K, et al. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry. 2000;68:423–428.
Pezzella FR, Colosimo C, Vanacore N, et al. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord. 2005;20:77–81.
Cilia R, Siri C, Canesi M, et al. Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome. J Neurol Neurosurg Psychiatry. 2014;85:311–318.
Warren N, O'Gorman C, Lehn A, et al. Dopamine dysregulation syndrome in Parkinson's disease: a systematic review of published cases. J Neurol Neurosurg Psychiatry. 2017;88:1060–1064.
Cools R, Barker RA, Sahakian BJ, et al. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex. 2001;11:1136–1143.
Evans AH, Pavese N, Lawrence AD, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol. 2006;59:852–858.
Robinson TE, Berridge KC. The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction. 2000;95(suppl 2):S91–S117.
DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004;26:649–666.
Mizushima J, Takahata K, Kawashima N, et al. Successful treatment of dopamine dysregulation syndrome with dopamine D2 partial agonist antipsychotic drug. Ann Gen Psychiatry. 2012;11:19.
Lertxundi U, Hernandez R, Medrano J, et al. Aripiprazole and impulse control disorders: higher risk with the intramuscular depot formulation?Int Clin Psychopharmacol. 2018;33:56–58.
Selfani K, Soland VL, Chouinard S, et al. Movement disorders induced by the “atypical” antipsychotic aripiprazole. Neurologist. 2017;22:24–28.
López-Torres E, Salomón J, Vicario F, et al. Aripiprazole-induced parkinsonism and its association with dopamine and serotonin receptor polymorphisms. J Clin Psychopharmacol. 2008;28:352–353.
Substance Nomenclature:: 0 (Antipsychotic Agents)
0 (Dopamine Agonists)
0 (Quinolones)
82VFR53I78 (Aripiprazole)
VTD58H1Z2X (Dopamine)
Entry Date(s):: Date Created: 20220209 Date Completed: 20220304 Latest Revision: 20220531
Update Code:: 20240104
DOI:: 10.1097/JCP.0000000000001519
PMID:: 35135978
: Czasopismo naukowe

Informacja